Stocks and Investing
Stocks and Investing
Mon, March 11, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Chris Shibutani Downgraded (AMLX) to Hold and Decreased Target to $4 on, Mar 11th, 2024
Chris Shibutani of Goldman Sachs, Downgraded "Amylyx Pharmaceuticals, Inc." (AMLX) to Hold and Decreased Target from $40 to $4 on, Mar 11th, 2024.
Chris has made no other calls on AMLX in the last 4 months.
There are 2 other peers that have a rating on AMLX. Out of the 2 peers that are also analyzing AMLX, 1 agrees with Chris's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Umer Raffat of "Evercore ISI Group" Downgraded from Buy to Hold on, Friday, March 8th, 2024
This is the rating of the analyst that currently disagrees with Chris
- Graig Suvannavejh of "Mizuho" Reiterated at Strong Buy with Increased Target to $32 on, Friday, March 8th, 2024
Contributing Sources